Search Results
Aug 20, 2026, 09:37 ET Lupin und Tenpoint Therapeutics geben strategische Partnerschaft zur Vermarktung von YUVEZZI™ in der Europäischen Union, dem Vereinigten Königreich, der Schweiz, Norwegen und Island bekannt
Brimonidintartrat-Augentropfen) 2,75 %/0,1 % ist ein einmal täglich anzuwendendes Zweikomponenten-Augentropfenpräparat, das von der US-amerikanischen Food & Drug Administration (FDA) zur Behandlung von Presbyopie zugelassen ist, einer Erkrankung, die durch den allmählichen Verlust der Nahsehschärfe gekennzeichnet
More news about: Lupin Limited
Aug 20, 2026, 09:09 ET Lupin et Tenpoint Therapeutics annoncent un partenariat stratégique visant à commercialiser YUVEZZI™ dans l'Union européenne, au Royaume-Uni, en Suisse, en Norvège et en Islande
2,75 % de carbachol et 0,1 % de tartrate de brimonidine) est un collyre à double principe actif, à prise unique quotidienne, approuvé par la Food & Drug Administration (FDA) des États-Unis pour le traitement de la presbytie, une affection caractérisée par une perte progressive de l'acuité visuelle de
More news about: Lupin Limited
Aug 20, 2026, 09:00 ET Aon: U.S. Employer Health Care Costs Continue Multi-Year Climb, Projected to Rise 9.5% in 2027
rise as utilization of health care services increases, chronic conditions become more prevalent and the numbers of high-cost claims grow. Prescription drug spending also remains a significant contributor, driven by growing use of specialty medications and continued adoption of GLP-1 therapies. As these
More news about: Aon plc
Aug 20, 2026, 09:00 ET The J.M. Smucker Co. Announces the Election of Jeff Varcoe to Senior Vice President, Science and Technical Excellence
to The J.M. Smucker Co. for packaged coffee products sold in retail channels such as grocery stores, mass merchandisers, club stores, e-commerce and drug stores, and in certain away from home channels. This information does not pertain to products for sale in Dunkin'® restaurants.
More news about: The J.M. Smucker Co.
Aug 20, 2026, 09:00 ET Benchling Brings Chemistry and Biology Together on One R&D Platform, Adds Chemistry Reactions and Predictive Models
models enable any chemist using Benchling to predict the chemical and pharmacokinetic properties that determine whether a molecule can become a viable drug. Inductive Bio's models are independently validated by three consecutive first place performances in the OpenADMET blind prediction challenges.Scientists
More news about: Benchling
Aug 20, 2026, 08:47 ET Amanda Owens Joins Precision for Medicine To Expand Access to Fit-for-Purpose Biospecimens for Advanced Research
demands deeply annotated biospecimens that are rich in genetic and molecular data. These higher standard biospecimens have become critical for advanced drug development.Owens brings extensive life sciences experience spanning biospecimen services, genomics, gene editing and advanced therapies, with
More news about: PRECISION FOR MEDICINE
Aug 20, 2026, 08:46 ET O'Shaughnessy Ventures Backs Scientist's Bid to Prevent Tick Bites
raised a $28.5 million Series A round. Today, Beyene is adjunct faculty in Northeastern University's Graduate Biotechnology Program, where he teaches drug development and scientific communication.OSV's founder and CEO, Jim O'Shaughnessy, commented, "Joseph's resilience, experience and ambition made
More news about: O'Shaughnessy Ventures
Aug 20, 2026, 08:30 ET Planning for Accelerated Approval: Timing is Everything, Upcoming Webinar Hosted by Xtalks
https://www.fda.gov/files/drugs/published/new-drug-therapy-2025-annual-report.pdfU.S. Food and Drug Administration. Advancing Health Through Innovation: New Drug Therapy Approvals 2024. Center for Drug Evaluation and Research; January 2025.
More news about: Xtalks
Aug 20, 2026, 08:30 ET Optimize Obesity Development: Endpoint Strategies for Early-phase Innovation to Late-phase Differentiation, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how endpoint selection can support obesity drug development from early- to late-phase trials. The featured speakers will discuss how patient-reported outcomes, glucose monitoring, cardiac assessments and medical imaging can help evaluate safety, efficacy and treatment
More news about: Xtalks
Aug 20, 2026, 08:10 ET West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
study and enables patient enrollment, which is expected in the coming weeks. ProSense® is the first and only medical device to be granted U.S. Food and Drug Administration ("FDA") marketing authorization for the local treatment of low-risk breast cancer with endocrine therapy in women aged 70 and above.The
More news about: IceCure Medical
Aug 20, 2026, 08:05 ET Maverix Medical Announces FDA 510(k) Clearance for the Narwhal™ Cryo System
/PRNewswire/ -- Maverix Medical, a company focused on revolutionizing the diagnosis and treatment of lung cancer, today announced that the U.S. Food and Drug Administration granted 510(k) clearance on June 30, 2026 for the Maverix Narwhal™ Cryo System, a single-use flexible cryoprobe that requires no console.
More news about: Maverix Medical
Aug 20, 2026, 08:04 ET PleoPharma Awarded $6.5 Million NIDA Grant to Support Phase 3 Trial of PP-01 for Cannabis Withdrawal in Patients with Cannabis Use Disorder
development company focused on cannabis-related health issues, today announced the award of a $6.5 million, three-year grant from the National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health (NIH). The funding will support the advancement of the company's pivotal Phase 3 CAN-004
More news about: PleoPharma, Inc
Aug 20, 2026, 08:00 ET Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
results from the study confirmed that AL001 matches blood levels of standard lithium carbonate, the reference drug, addressing U.S. Food and Drug Administration regulatory requirements for a new drug formulation, as well as providing a differentiated, potential dose-sparing benefit profile for patients.AL001:
More news about: Alzamend Neuro, Inc.
Aug 20, 2026, 08:00 ET Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation,
More news about: Nuvation Bio Inc.
Aug 20, 2026, 08:00 ET Superior HealthPlan has supported more than 312,000 Texas pregnancies since 2022 through the Start Smart for Your Baby® program
postpartum appointments.Connections to community resources for food, diapers and clothing.Assistance to help quit smoking, alcohol or drug use.Transportation to and from doctor visits (where available).To learn more, visit
More news about: Superior HealthPlan
Aug 20, 2026, 08:00 ET Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland
YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a once-daily, dual-agent eye drop approved by the U.S. Food & Drug Administration (FDA) for the treatment of presbyopia, a condition characterized by the gradual loss of near vision acuity that typically begins around
More news about: Lupin Limited
Aug 20, 2026, 07:45 ET Radiopaque, Polymer-Based Embolic Coil Tops 125 Implants, With Minimal Artifacts in CT, MRI Imaging
for peripheral vascular and neurovascular uses in the interventional radiology market. The company received 510(k) clearance from the U.S. Food and Drug Administration for its embolization coil device in 2025.Media contact: Aimee Bennett,
More news about: Embolization, Inc.
Aug 20, 2026, 07:30 ET Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides
platform is in the development stage. All candidates described are investigational and have not been approved for any indication by the U.S. Food and Drug Administration or any other regulatory body. No clinical studies have been conducted, and nothing in this release should be understood as a claim of
More news about: Vector Sciences & Therapeutics
Aug 20, 2026, 07:30 ET Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe
forward to evaluating its clinical efficacy, safety, and tolerability in this pivotal study."XIAFLEX is currently approved by the U.S. Food & Drug Administration for urological and orthopedic conditions. XIAFLEX is investigational for the treatment of hammer toe and has not been approved by the
More news about: Keenova Therapeutics
Aug 20, 2026, 07:29 ET Ping An Reports 1H 2026 Results
diseases; 5. medical visit guidance which assists in seeking medical care; 6. smart guard which ensures home safety; and 7. global medical consultation and drug sourcing which offers access to premium resources.
More news about: Ping An Insurance (Group) Company of China, Ltd.
Aug 20, 2026, 07:21 ET Ping An Reports 1H 2026 Results
diseases; 5. medical visit guidance which assists in seeking medical care; 6. smart guard which ensures home safety; and 7. global medical consultation and drug sourcing which offers access to premium resources.
More news about: Ping An Insurance (Group) Company of China, Ltd.
Aug 20, 2026, 07:05 ET IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
minimizing systemic exposure.About SRGelSRGel is IntraGel's proprietary injectable hydrophobic gel-like drug delivery platform designed to enable sustained, tailored drug release. Built on a proprietary water-free and solvent-free fatty-acids based polymer matrix, SRGel is engineered to
More news about: IntraGel Therapeutics
Aug 20, 2026, 07:00 ET Matwings Demonstrates Closed-Loop Protein AI Through Four AI-Wet Lab Cycles and 222 Protein Variants
relevant to drug development."About MatwingsShanghai Matwings Technology Co., Ltd. is an AI-driven protein R&D company integrating specialist AI models, computational molecular design and experimental validation to support iterative protein engineering and drug development.For
More news about: Shanghai Matwings Technology Co., Ltd.; Shanghai Biowings Therapeutics Co., Ltd.
Aug 20, 2026, 05:00 ET Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland
YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a once-daily, dual-agent eye drop approved by the U.S. Food & Drug Administration (FDA) for the treatment of presbyopia, a condition characterized by the gradual loss of near vision acuity that typically begins around
More news about: Lupin Limited
Aug 20, 2026, 02:22 ET Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Development of AKIR001 for the Treatment of Solid Tumors
significant step in advancing the program designed to address a primary driver of aggressive cancers."AKIR001 is a targeted radiopharmaceutical drug candidate that combines the therapeutic radioisotope n.c.a. Lu-177 with a proprietary antibody targeting CD44v6, a cancer marker associated with several
More news about: Akiram Therapeutics